TELESTA THERAPEUTICS INC T.TST

more FDA signposts...SRPT...

[thathurt]

SRPT is a competitor to BMRN in the DMD space...SRPT has an Adcom next week or so...FDA released briefing documents yesterday and was negative...SRPT down 50% today before Adcom...

..so go back to TST FDA briefing documents when released TST had limited to no price reaction (i believe it had moved briefly from $0.80 to $1.00 on some pumper idiocy about some supposed Japan partnership) ...and TST documents were net-net positive toward MCNA

..regards

[thathurt]

forgot to add.. .if you read both BMRN and SRPT briefing documents the FDA (by SOP i would say) i very clear and consistent with its thinking... BRMN it clearly stated it believed that drug to be unsafe and with SRPT it clearly states it believes that drug to not be efficacious (both is their interesting stats approach)...it was if i remember correclty indicating re. MCNA that is "might have